227 related articles for article (PubMed ID: 29691733)
1. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
2. Failure to Treat: Audit of an Institutional Cancer Registry Database at a Large Comprehensive Cancer Center Reveals Factors Affecting the Treatment of Pancreatic Cancer.
Miller-Ocuin JL; Zenati MS; Ocuin LM; Varley PR; Novak SM; Winters S; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2017 Aug; 24(8):2387-2396. PubMed ID: 28534079
[TBL] [Abstract][Full Text] [Related]
3. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes.
Visser BC; Ma Y; Zak Y; Poultsides GA; Norton JA; Rhoads KF
HPB (Oxford); 2012 Aug; 14(8):539-47. PubMed ID: 22762402
[TBL] [Abstract][Full Text] [Related]
4. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
7. Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.
Khorfan R; Cooke DT; Meguid RA; Backhus L; Varghese TK; Farjah F; Bilimoria KY; Odell DD;
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):649-660.e8. PubMed ID: 34144822
[TBL] [Abstract][Full Text] [Related]
8. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?
Bertens KA; Massman JD; Helton S; Garbus S; Mandelson MM; Lin B; Picozzi VJ; Biehl T; Alseidi AA; Rocha FG
J Surg Oncol; 2018 Jun; 117(8):1655-1663. PubMed ID: 29761510
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
10. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
[TBL] [Abstract][Full Text] [Related]
11. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
[TBL] [Abstract][Full Text] [Related]
12. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals.
Elshami M; Hoehn RS; Ammori JB; Hardacre JM; Selfridge JE; Bajor D; Mohamed A; Chakrabarti S; Mahipal A; Winter JM; Ocuin LM
HPB (Oxford); 2023 Dec; 25(12):1502-1512. PubMed ID: 37558565
[TBL] [Abstract][Full Text] [Related]
13. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma.
Ahola R; Siiki A; Vasama K; Vornanen M; Sand J; Laukkarinen J
Br J Surg; 2017 Oct; 104(11):1532-1538. PubMed ID: 28517236
[TBL] [Abstract][Full Text] [Related]
14. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
[TBL] [Abstract][Full Text] [Related]
15. Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Shen C; Santry H; Bridges J; Dillhoff M; Ejaz A; Pawlik TM; Tsung A
J Natl Compr Canc Netw; 2020 May; 18(5):556-563. PubMed ID: 32380462
[TBL] [Abstract][Full Text] [Related]
16. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
17. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
[TBL] [Abstract][Full Text] [Related]
18. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
19. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
[TBL] [Abstract][Full Text] [Related]
20. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
